Coston McIsaac & Partners Trims Position in Pfizer Inc. (NYSE:PFE)

Coston McIsaac & Partners reduced its position in Pfizer Inc. (NYSE:PFE) by 16.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,994 shares of the biopharmaceutical company’s stock after selling 3,099 shares during the period. Coston McIsaac & Partners’ holdings in Pfizer were worth $424,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. AQR Capital Management LLC increased its stake in shares of Pfizer by 1.6% during the 2nd quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after acquiring an additional 9,435 shares during the last quarter. Quarry LP purchased a new stake in Pfizer in the second quarter valued at approximately $31,000. Dana Investment Advisors Inc. increased its position in Pfizer by 9.6% during the second quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after purchasing an additional 8,771 shares during the last quarter. Souders Financial Advisors raised its stake in Pfizer by 6.1% during the second quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 483 shares during the period. Finally, Birmingham Capital Management Co. Inc. AL boosted its holdings in shares of Pfizer by 0.9% in the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 181,763 shares of the biopharmaceutical company’s stock valued at $5,086,000 after purchasing an additional 1,559 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE opened at $26.65 on Thursday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $151.00 billion, a PE ratio of 36.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a fifty day simple moving average of $26.18 and a 200 day simple moving average of $27.91.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Guggenheim reduced their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.